The treatable intellectual disability APP www.treatable-id.org: A digital tool to enhance diagnosis & care for rare diseases by Clara D M van Karnebeek et al.
van Karnebeek et al. Orphanet Journal of Rare Diseases 2012, 7:47
http://www.ojrd.com/content/7/1/47RESEARCH Open AccessThe treatable intellectual disability
APP www.treatable-id.org: A digital tool to
enhance diagnosis & care for rare diseases
Clara D M van Karnebeek1,2,5*, Roderick F A Houben2,3,5, Mirafe Lafek1,2,5, Wynona Giannasi2,4,5 and
Sylvia Stockler1,2,5Abstract
Background: Intellectual disability (ID) is a devastating and frequent condition, affecting 2-3% of the population
worldwide. Early recognition of treatable underlying conditions drastically improves health outcomes and decreases
burdens to patients, families and society. Our systematic literature review identified 81 such inborn errors of
metabolism, which present with ID as a prominent feature and are amenable to causal therapy. The WebAPP
translates this knowledge of rare diseases into a diagnostic tool and information portal.
Methods & results: Freely available as a WebAPP via www.treatable-id.org and end 2012 via the APP store, this
diagnostic tool is designed for all specialists evaluating children with global delay / ID and laboratory scientists.
Information on the 81 diseases is presented in different ways with search functions: 15 biochemical categories,
neurologic and non-neurologic signs & symptoms, diagnostic investigations (metabolic screening tests in blood
and urine identify 65% of all IEM), therapies & effects on primary (IQ/developmental quotient) and secondary
outcomes, and available evidence For each rare condition a ‘disease page’ serves as an information portal with
online access to specific genetics, biochemistry, phenotype, diagnostic tests and therapeutic options. As new
knowledge and evidence is gained from expert input and PubMed searches this tool will be continually updated.
The WebAPP is an integral part of a protocol prioritizing treatability in the work-up of every child with global delay
/ ID. A 3-year funded study will enable an evaluation of its effectiveness.
Conclusions: For rare diseases, a field for which financial and scientific resources are particularly scarce, knowledge
translation challenges are abundant. With this WebAPP technology is capitalized to raise awareness for rare
treatable diseases and their common presenting clinical feature of ID, with the potential to improve health
outcomes. This innovative digital tool is designed to motivate health care providers to search actively for treatable
causes of ID, and support an evidence-based approach to rare metabolic diseases. In our current –omics world with
continuous information flow, the effective synthesis of data into accessible, clinical knowledge has become ever
more essential to bridge the gap between research and care.
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Intellectual disability (ID) is a life-long and debilitating
condition with deficits in cognitive functioning (IQ< 70)
and adaptive skills [1,2]. ID is often associated with be-
havioural problems (autism, hyperactivity, aggressivity
and self-injurious behaviour), epilepsy and other neuro-
logical disabilities, all resulting in psychological, social
and economic burdens [3,4]. In children <5 yrs of age
with deficits in two or more developmental domains (e.
g. fine/gross motor skills, speech, interaction, etc.), the
term global developmental delay (DD) is applied [5].
Here we will use the term ID collectively for both ID
and DD. ID is frequent, affecting 2-3% of children and
adults worldwide and is the disease category with one of
the largest health care costs [6]. The etiology of ID is di-
verse, including infectious, traumatic and toxic causes.
Genetic etiologies constitute the most frequent cause
and are demonstrable in more than 50% of individuals
with ID [7], ranging from numeric and structural
chromosomal abnormalities and submicroscopic Copy
Number Variants to methylation abnormalities, and to
single gene defects [8].
Current guidelines aimed at structuring the evaluation
of genetic causes of ID are based on frequencies of single
conditions and yield of diagnostic methods and proce-
dures [9]. Therefore, karyotyping and array-comparative
genomic hybridisation, which yield a causal diagnosis in
20% of cases, is standard practice as part of the first-line
investigation [10,11]. Unfortunately these high diagnostic
yields do not translate into therapeutic benefit, as at the
present time, causal therapy is not available for most
conditions identified by these investigations. One cat-
egory of genetic conditions is amenable to treatment
however: inborn errors of metabolism (IEM).
However, because the single conditions are rare (e.g.
Phenylketonuria 1:10.000) to ultrarare (e.g. Guanidinoa-
cetate methyltransferase (GAMT) deficiency 1:200.000)
and diagnosis is considered complicated and expensive,
they are not systematically screened in a child with ID
[12]. Expanded newborn screening covers some but by
far not all of them, and may miss mild forms of disease.
In order to assess the number of currently treatable
IDs we recently performed a systematic literature review,
and identified 81 treatable IEM with ID as a major clin-
ical feature [13]. While 60% of these conditions can be
detected through a panel of widely available screening
tests on blood and urine (e.g. aminoacids, homocysteine,
copper, ceruloplasmin, organic acids, purines & pyrimi-
dines, creatine & guanidinoacteate, glycosaminoglycans
& oligosaccharides), for the remaining 35% conditions
(n = 28) a ‘single test per single disease’APProach includ-
ing single metabolite or primary molecular analysis is
required. Because these tests may be difficult to obtain,
and / or require extensive funding, and / or requireinvasive sampling procedures (spinal tap for cerebro-
spinal fluid collection, skin biopsy to cultivate fibro-
blasts), a clinical differential diagnosis is needed to
provide efficiency in the diagnostic work up.
To mitigate the complexity and time-consuming na-
ture of this task we have created a downloadable
WebAPP www.treatable-id.org with the aim of facilitat-
ing the recognition of treatable ID and maximizing the
efficiency of diagnostic work up. Providing an interactive
tool for both clinicians and scientists this tool is
intended to help to increase the general awareness of
treatable ID and to create a reliable information portal
for rare metabolic diseases.
Methods & results
For the detailed methodology with results of our system-
atic literature review, the reader is referred to: Molecular
Genetics and Metabolism 2012 Mar;105(3):368–81, in
pdf version freely downloadable via: http://www.science-
direct.com/science/article/pii/S1096719211006081
Parameters We designed the digital APPlication for a
target audience including all specialists evaluating children
with ID (general and developmental pediatricians, neurol-
ogists, geneticists, metabolic specialists) as well as labora-
tory scientists, ranging from student to expert level.
We created menus showing the conditions according
to biochemical categories, clinical signs & symptoms,
diagnostic tests as well as therapies and evidence. We
created a disease page for each of the 81 treatable IDs
including providing a detailed information portal with
information on all aspects of the particular rare disease
with links to internationally accepted resources.
Technology The WebAPP was created using the latest
web standards and is best viewed in the latest version of
all major browsers (Explorer 8+, Safari, Chrome & Fire-
fox). Furthermore the APP is designed such that it is
easily accessible on all major tablets, e.g. the Apple
iPpad. This whole process was supported and funded by
the ‘Metakids Foundation’ in The Netherlands (www.
metakids.nl).
The Digital Tool is freely available as a WebAPP via
www.treatable-id.org. Users are requested to register on-
line. In the middle of 2012 this tool will also be down-
loadable via the iOS & Android APP stores for use on
mobile devices.
The APP will be updated (with novel data on diseases,
diagnostics, treatments, evidence) at 3 month-intervals
by performing predesigned searches in PubMed and
selections according to previously described strategies.
Users are asked for feedback and input via email and
international experts will be asked to update and
van Karnebeek et al. Orphanet Journal of Rare Diseases 2012, 7:47 Page 3 of 7
http://www.ojrd.com/content/7/1/47maintain particular disease pages (see below) which will
be incorporated for continuous improvement.
Design & use
The collective information on the diseases, causally
related to ID and amenable to treatment, is presented in
several different ways as shown in Figure 1.
I) Biochemical Categories
The treatable diseases are presented in 15 biochemical
categories according to accepted nomenclature and/or
pathophysiology. For each disease the biochemical defect
is listed, with illustration thereof provided on the ‘disease
page’.
II) Neurologic and Non-Neurologic Signs & Symptoms
The clinical features for all rare diseases are divided
into neurological and non-neurological signs and symp-
toms. For each rare disease only the most characteristic,
specific and consistent features are listed.
Neurologic features include ataxia, behavioural disturb-
ance, dementia, dystonia, encephalopathic crisis, epi-
lepsy, hearing loss, hypotonia/myopathy, neuro-imaging
abnormalities (basal ganglia, cerebellum, cerebrum,
cysts/dysgenesis, white matter, mixed), neuropathy,Figure 1 WebAPP as knowledge translation tool to enhance diagnosi
include: biochemical group, signs & symptoms, diagnostic tests, treatmentocular movement abnormality, psychiatric disturbance,
sensorineural hearing loss, spasticity, stroke, vision loss.
All IEM except one (Tyrosinemia type II) are associated
with at least one additional prominent neurologic fea-
ture, of which the most frequent are epilepsy and various
types and degrees of movement disorders (e.g. spasticity,
dyskinesia, ataxia, etc). However, many of these condi-
tions can present with ID as sole feature for a consider-
able time prior to manifestation of the full phenotype. A
limitation of the list is the fact that in most case reports
and series, the clinical presentation of the epileptic
symptomatology and behavioural/psychiatric manifesta-
tions of IEM is poorly described. None are pathogno-
monic for a particular treatable ID. Due to this lack of
knowledge, it is currently not possible to provide more
detail on these particular signs and symptoms.
The non-neurologic features affect the following ana-
tomic / organ systems: bones and joints, dermatology,
endocrinology, eye, facial dysmorphism, growth & stat-
ure, heart, gastrointestinal, haematology, immunology,
kidney, liver, odour. For 69% of the treatable IEM, a
non-neurologic feature is a prominent part of the
phenotype.
In general, it is emphasized that that absence or pres-
ence of specific signs and / or symptoms not fitting the
list does not rule out the specific disorder in a patient.
Also, these data are subject to change as new diagnostics and treatment of intellectual disabilities. The interactive menus
& evidence.
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phenotypic presentation and natural history of metabolic
diseases, and will be updated accordingly.
It is also possible to search for a specific combination
of signs and symptoms. This feature, highly valued by
physicians in a baseline user survey, uses a search engine
and displays the disease pages on this site that contain
the signs and symptoms entered. This feature will be
continuously improved based on user feedback and
search input.
Finally, to further support the clinician in narrowing
down the differential diagnosis, the APP displays a di-
chotomy: those identifiable by routine metabolic screen-
ing tests (white background) versus those requiring a
specific test (green background). Thus the physician can
immediately discard the ‘IEM with white background
from the differential’ if routine metabolic screening was
negative.
III)Diagnostic Tests
To facilitate a practical guide for biochemical and gen-
etic diagnosis, the tests required for the diagnosis of
each of the conditions were assessed. Accordingly, dis-
eases were categorized into those diagnosed via ‘meta-
bolic screening tests’ versus those diagnosed via a ‘single
test per single disease’ approach.
Screening Tests were defined as those tests in blood
and urine, which are readily available in biochemical la-
boratories in most developed countries, and with a yield
of at least 2 IEM (and up to 22) per test, such as: plasma
amino-acids and total homocysteine, copper, ceruloplas-
min, urine organic acids, oligosaccharides, glycosamino-
glycans, purines/pyrimidines, creatine metabolites
(acylcarnitine profile may support these diagnosis but
does not independently identify one of these IEM).
Overall, these screening tests reliably provide clues for
diagnosis for 65% of all treatable IDs.
For the remaining treatable conditions, a specific ‘one
test per one disease’ approach is required. These diseases
are listed accordingly under Specific Tests (including
urine oligosaccharides and glycosaminoglycans). At the
time of publication of our review in 2012, primary gene
analysis is the most reliable approach for 13 IEM (20
genes). Each disease button lists the causal gene(s) as
well as the diagnostic test required.
In general, for most of the 81 diseases further con-
firmatory (biochemical / genetic) testing is needed for a
definitive diagnosis.
IV)Therapies
The diseases are listed in alphabetical order with the fol-
lowing information for each: therapeutic modality/-ies,(ranging from supplements, diets, substrate inhibition to
stem cell transplantation), level of evidence (ranging
from 1 and 2 (20%) to 4–5 (majority), clinical practice
(standard of care versus on an individual basis), effect
on predefined primary (IQ/developmental quotient) and
secondary (epilepsy, behavioural/psychiatric disturbances
etc) outcomes.
V) Disease Page
As illustrated by Figure 2, for each condition a ‘Disease
Page’ has been designed as an information portal com-
prising an overview of all signs and symptoms, a figure
showing the effected biochemical pathway, information
on available diagnostic tests and causal therapies. In
addition each page contains numerous online resources,
including Orphanet, OMIM, Gene Reviews, Online Scri-
ver, Gene Cards, journal articles, clinical trials, and pa-
tient resource websites.
Evaluation and knowledge translation
Before launching the APP in our institution, the BC
Children’s Hospital, a baseline survey, designed by an in-
dependent evaluator, was conducted with attending staff
and trainees from Medical Genetics, Developmental
Pediatrics, Neurology, Biochemical Genetics / Metabolic
Diseases, Child Psychiatry (N= 15) to determine current
practice and experience in the diagnostic evaluation of
(treatable) ID. Findings indicated the volume of patients
(mean: 8 per month), time spent searching for a diagno-
sis (mean: 3 hours, but at times exceeding 6 hrs), time
spent confirming a diagnosis (mean: 11 months), and
the proportion of causal diagnoses established (just over
a quarter (28%) of cases). This data forms the baseline
and will serve as a reference point for the diagnostic
evaluation of ID prior to the APP.
Three focus groups were conducted with the same
audience with the intent to determine clinicians’ initial
feedback on the usability of the APP as well as comfort
level with diagnosing and managing treatable IDs [14].
Via semi-structured interviews, users also were asked for
their perceptions on functionality of the APP as well as
suggestions for improving the uptake and usage of the
APP [15]. Based on user feedback we integrated the fol-
lowing suggestions to optimize the current version of the
APP: 1) search functions by signs and symptoms to help
formulate a differential diagnosis; 2) possibility to save
differential diagnoses for later comparison; 3) access via
APP to trusted resources such as the most commonly
used bibliographic databases (i.e. PubMed / Medline /
Ovid Medline) and disease specific databases and on-line
resources (i.e. OMIM, Gene Reviews, Scriver/OMMBID).
To enhance knowledge translation we have partnered
with Child Health BC, a network of agencies working to
Figure 2 ‘Disease Page’ as information portal for each rare inborn error of metabolism. As an example, the page with specific features and
online resources for Niemann Pick Disease Type C is presented here. Levels of Evidence are defined as follows: (source: Centre for Evidence-Based
Medicine, Oxford UK, www.cebm.net): Level 1a = Systematic Review of Randomized Controlled Trials (RCT), 1b = Individual RCT, 1c = ‘All or None’
(=(prolongation of) survival with therapy); Level 2a = Systematic Review of Cohort Studies, 2b = Individual Cohort Study, 2c = ‘Outcomes
Research’ (focused on end results of therapy for chronic conditions, including functioning and quality of life (http://www.ahrq.gov/clinic.outfact.
htm)); Level 3 = Systematic Review of Case–control Studies; Level 4 = Individual Case–control Study or Case-series/report; Level 4-5 = Single Case
Report; Level 5 = Expert opinion without critical appraisal.
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children and youth in the province of British Columbia,
for the provision of capacity to support province-wide
education and knowledge translation among General
Practitioners, community pediatricians and specialists.
These 3 groups of physicians will work collaboratively to
achieve consensus on 1st tier metabolic screening for
treatable IEM in all ID patients, communication path-
ways and appropriate referral to a tertiary care centre for
further evaluation or treatment.Conclusions
Being mindful of the gap
Despite continuous efforts to transform new insights
generated by medical research into evidence-based clin-
ical practice, this has proven difficult and has seldom
translated into improved health outcomes [16,17]. For
rare diseases, a field for which financial and scientific
resources are particularly scarce, this gap is even more
pronounced. Inherent to rare diseases the following
challenges present itself: How can knowledge translation
and dissemination be improved in a field in which: a)
biological pathways are complicated and numerous; b)
patients, as well as the physicians managing and scien-
tists studying their diseases, are small in number, and
internationally dispersed; c) clinical trials are few and far
between; and hence d) evidence is limited?Time is Brain
New digital and social media, with the endless capacity
to centralize information and connect people, provides
an exciting new solution to these issues (e.g. Orphanet).
With this APP we capitalize on technology to raise
awareness for these rare treatable diseases, their com-
mon presenting clinical feature of ID, as well as the need
for early diagnosis (‘Time is Brain’) to directly improve
health outcomes.
This innovative digital tool is designed to motivate
health care providers to search actively for treatable
causes of ID, and support an evidence-based approach
to rare metabolic diseases. In our current –omics world
with continuous information flow, effective synthesis of
data into accessible, clinical knowledge has become ever
more essential to bridge the gap between research and
care [18].Current applications
This APP was designed as part of our Treatable Intellec-
tual Disability Endeavour (TIDE-BC; www.tidebc.org) re-
search and care project. This funded project aims to
improve health outcomes of all children with ID in the
province of British Columbia, Vancouver through
improved diagnosis and treatment. The APP is used by
specialists in our institution as an essential part of our
TIDE protocol, which was designed in consensus with
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tier testing for treatable IDs to current international
guidelines [8,11].
Evaluation & ongoing improvement
To continuously improve and evaluate the impact of the
tool, a mixed methodology evaluation will be conducted
amongst online users and a local focus group, utilizing
both formative and summative approaches. [15] Primary
care physicians and specialists will be asked to provide
their feedback on the utility of the APP in supporting
the diagnostic evaluation. After registration online users
are requested to provide feedback on the usefulness and
applicability of the tool in their daily practice to support
diagnosis and treatment of children with ID via the on-
line APP feedback form. User visits to the site will also
be tracked focusing on page usage (and non usage) and
key search terminology (including signs and symptoms).
The APP will be updated (with novel data on diseases,
diagnostics, treatments, evidence) at 3 month-intervals,
and improved through incorporation of data generated
by our evaluation activities.
Towards empowerment & better health outcomes
In the future this APP may be converted into an inter-
active information portal for patients and families, espe-
cially as new digital and social media (Twitter, blogs etc.)
offer novel approaches to reaching and uniting rare dis-
ease patients from across the globe. Proven avid web
users, patients / families in the rare diseases community
may ultimately utilize new media as a vehicle for em-
powerment and to enable and better health outcomes.
By increasing access to a larger volume of patients for
clinical trials and increasing relevance of health out-
comes studied and improved evaluation thereof, current
research disseminated using innovative technologies will
be effectively used to drive patient care improvements
forward.
It is the hope that ‘one louder voice’ will support pol-
icymakers to make evidence based decisions that will re-
sult in the allocation of financial, scientific, and care
resources to the rare diseases community.
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